The present invention relates to a method predictive of response to treatment with ustekinumab in a patient affected from psoriasis comprising detecting in the genome of the subject the association of the HLA-Cw* 0602 allele and a single nucleotide polymorphism predictive of response to said biological drug. The method according to the invention is indicative of greater likelihood of clinical response to treatment, speed of clinical response to treatment and better maintenance to the therapeutic effects dell'ustekinumab and/or drugs blocking the IL12/23-IL17 axis.
Marinari, B., Talamonti, M., Costanzo, A., Botti, E. (2015). Genetic markers predictive of clinical response to biological drugs in psoriasis.
Genetic markers predictive of clinical response to biological drugs in psoriasis.
Barbara MARINARI;Marina TALAMONTI;Elisabetta Botti
2015-12-01
Abstract
The present invention relates to a method predictive of response to treatment with ustekinumab in a patient affected from psoriasis comprising detecting in the genome of the subject the association of the HLA-Cw* 0602 allele and a single nucleotide polymorphism predictive of response to said biological drug. The method according to the invention is indicative of greater likelihood of clinical response to treatment, speed of clinical response to treatment and better maintenance to the therapeutic effects dell'ustekinumab and/or drugs blocking the IL12/23-IL17 axis.| File | Dimensione | Formato | |
|---|---|---|---|
|
PCTIB2015059573.pdf
solo utenti autorizzati
Licenza:
Copyright dell'editore
Dimensione
169.68 kB
Formato
Adobe PDF
|
169.68 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
